1. 1574Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis. (December 2014) Authors: Lalezari, Jacob; Latiff, Gulam H; Brinson, Cynthia; Echevarría, Juan; Treviño-Pérez, Sandra; Bogner, Johannes R; Stock, David; Joshi, Samit R; Hanna, George J; Lataillade, Max Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 540HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis. (December 2014) Authors: Brinson, Cynthia; Lalezari, Jacob; Latiff, Gulam H; Thompson, Melanie; Echevarría, Juan; Treviño-Pérez, Sandra; Stock, David; Joshi, Samit R; Hanna, George J; Lataillade, Max Journal: Open forum infectious diseases Issue: Volume 1(2014)Supplement 1 Page Start: S22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection. Issue 5 (3rd October 2022) Authors: Krystal, Mark; Chabria, Shiven; Austin, Daren; Wolstenholme, Allen; Wensel, David; Lataillade, Max; Abberbock, Judah; Baker, Mark; Ackerman, Peter Journal: Antiviral therapy Issue: Volume 27:Issue 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc. (1st January 2022) Authors: Rose, Ronald; Gartland, Margaret; Li, Zhufang; Zhou, Nannan; Cockett, Mark; Beloor, Jagadish; Lataillade, Max; Ackerman, Peter; Krystal, Mark Journal: AIDS Issue: Volume 36:Number 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc. (1st January 2022) Authors: Rose, Ronald; Gartland, Margaret; Li, Zhufang; Zhou, Nannan; Cockett, Mark; Beloor, Jagadish; Lataillade, Max; Ackerman, Peter; Krystal, Mark Journal: AIDS Issue: Volume 36:Number 1(2022) Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. Issue 12 (December 2015) Authors: Pavia-Ruz, Noris; Rossouw, Magdel; Sáez-Llorens, Xavier; Bunupuradah, Torsak; Taylor, Mathew; Yang, Rong; Sevinsky, Heather; Krystal, Mark; Lataillade, Max; Seekins, Daniel; Biguenet, Sophie Journal: Pediatric infectious disease journal Issue: Volume 34:Issue 12(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. Issue 1 (January 2016) Authors: Gupta, Samir K; McComsey, Grace A; Lombaard, John; Echevarría, Juan; Orrell, Catherine; Avihingsanon, Anchalee; Osiyemi, Olayemi; Santoscoy, Mario; Ray, Neelanjana; Stock, David A; Joshi, Samit R; Hanna, George J; Lataillade, Max Journal: Lancet Issue: Volume 3:Issue 1(2016) Page Start: e13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women. Issue 4 (21st September 2021) Authors: Pene Dumitrescu, Teodora; Greene, Thomas J.; Joshi, Samit R.; Xu, Jianfeng; Johnson, Mark; Halliday, Fiona; Butcher, Laurie; Zimmerman, Eric; Webster, Lindsey; Pham, Theresa T.; Lataillade, Max; Min, Sherene Other Names: Bies Rob guestEditor.; Wright Dan guestEditor. Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 4(2022) Page Start: 1704 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. (1st June 2021) Authors: Ackerman, Peter; Thompson, Melanie; Molina, Jean-Michel; Aberg, Judith; Cassetti, Isabel; Kozal, Michael; Castagna, Antonella; Martins, Marcelo; Ramgopal, Moti; Sprinz, Eduardo; Treviño-Pérez, Sandra; Streinu-Cercel, Adrian; Latiff, Gulam H.; Pialoux, Gilles; Kumar, Princy N.; Wang, Marcia; Chabr... Journal: AIDS Issue: Volume 35:Number 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults. Issue 9 (4th March 2021) Authors: Pene Dumitrescu, Teodora; Joshi, Samit R.; Xu, Jianfeng; Greene, Thomas J.; Johnson, Mark; Butcher, Laurie; Zimmerman, Eric; Webster, Lindsey; Pham, Theresa T.; Lataillade, Max; Min, Sherene Journal: British journal of clinical pharmacology Issue: Volume 87:Issue 9(2021) Page Start: 3501 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗